-
This is an open label extension of 306 subjects from a previously reported delayed-start phase III clinical trial of rasagiline in early Parkinson's disease. Clinical benefit observed at one year in the early vs. delayed-start arm was maintained over an average 3.6 ± 2.1 years observation, raising the question of whether earlier intervention with rasagiline results in better outcomes.
-
In this study, there is no correlation between the risk of recurrent stroke and the size of a PFO, the magnitude of the right-to-left shunt, or the presence of an atrial septal aneurysm.
-
-
This issue deals with a common but often frustrating and unrewarding condition that confronts primary care physicians: fibromyalgia.
-
-
Drug combinations for hypertension; tenecteplase for out-of-hospital cardiac arrest; CAM most commonly used for back, neck, and arthritis pain; FDA Actions.
-
-
-
Imagine a new disease strikes your community that significantly increases mortality rates, particularly in critically ill patients. This same disease causes patients to suffer more pain, greater heart damage from a myocardial infarction, and, if they are elderly, increases the chance they will be discharged to a nursing home. Such a disease clearly would grab the public's attention, and even in these difficult times, money would be diverted to find a cure. This problem exists today in many of our communities: crowding.
-
The FDA has approved fesoterodine fumarate for the treatment of overactive bladder.